MARKET

LEGN

LEGN

Legend Biotech Corp
NASDAQ
18.62
-0.49
-2.56%
After Hours: 18.62 0 0.00% 18:26 09/28 EDT
OPEN
18.80
PREV CLOSE
19.11
HIGH
18.89
LOW
18.40
VOLUME
1.71M
TURNOVER
--
52 WEEK HIGH
37.50
52 WEEK LOW
16.24
MARKET CAP
3.62B
P/E (TTM)
-36.9518
1D
5D
1M
3M
1Y
5Y
1D
Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Ocugen (OCGN)
TipRanks · 14h ago
Weekly Report: what happened at LEGN last week (0921-0925)?
Weekly Report · 14h ago
Legend Biotech (LEGN) On CARVYKTI Follow Up Data And The Case For A Reset Valuation
Simply Wall St · 15h ago
Legend Biotech Reports Five-Year CARVYKTI Survival Data in Earlier-Line Myeloma
TipRanks · 3d ago
Legend Biotech announces five-year follow-up data from Cartitude-2 Cohort A
TipRanks · 3d ago
Legend Biotech Reports 50% Of CARTITUDE-2 Patients Remained Progression-Free At 5 Years After Single CARVYKTI Infusion
Benzinga · 3d ago
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
Barchart · 3d ago
Legend Biotech Shareholders Back Board Slate and Expand Equity Plan at 2026 AGM
TipRanks · 4d ago
More
About LEGN
Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

Webull offers Legend Biotech Corp (ADR) stock information, including NASDAQ: LEGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LEGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LEGN stock methods without spending real money on the virtual paper trading platform.